Related Experiment Video
Updated: Jan 11, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Rational Design and Biological Evaluation of a Novel Polθ Polymerase Inhibitor for Synergistic Targeting of
Ziheng Yu1, Zhen Li2, Lei Jiang2
1School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, PR China.
Abstract:
DNA polymerase theta (Polθ) is a key enzyme in the theta-mediated end-joining (TMEJ) and a promising target for synthetic lethality-based cancer therapy, particularly in homologous recombination (HR)-deficient tumors. Herein, we designed and optimized a series of Polθ polymerase inhibitors, exploiting a previously unexplored binding pocket to enhance potency, cellular activity, and pharmacokinetics. Compound 33 exhibited low-nanomolar Polθ inhibition, strong antiproliferative activity in DLD1 BRCA2 KO cells, and high sensitivity to MDA-MB-436 cells. In combination with Olaparib, it significantly enhanced DNA damage accumulation, induced γH2AX levels, and achieved 85% tumor growth inhibition (TGI) in the MDA-MB-436 xenograft model. Pharmacokinetic studies confirmed a favorable dose-dependent profile, and preliminary safety evaluations indicated good tolerability. These findings establish compound 33 as a potent Polθ inhibitor with strong synthetic lethality effects, supporting its further preclinical development as a novel Polθ-targeted therapeutic agent.
Insights
Researchers developed a novel DNA polymerase theta (Polθ) inhibitor, compound 33. This potent inhibitor shows promise for synthetic lethality cancer therapy, especially in homologous recombination-deficient tumors.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- DNA polymerase theta (Polθ) is crucial for theta-mediated end-joining (TMEJ).
- Polθ is a potential therapeutic target for synthetic lethality in cancer, particularly in homologous recombination (HR)-deficient tumors.
Purpose of the Study:
- To design and optimize novel Polθ inhibitors.
- To enhance inhibitor potency, cellular activity, and pharmacokinetics by targeting a new binding pocket.
Main Methods:
- Design and synthesis of Polθ inhibitors.
- In vitro enzyme inhibition assays.
- Cellular proliferation assays in cancer cell lines (DLD1 BRCA2 KO, MDA-MB-436).
- Combination therapy studies with Olaparib in a xenograft model.
- Pharmacokinetic and preliminary safety evaluations.
Main Results:
- Compound 33 demonstrated low-nanomolar Polθ inhibition.
- It showed strong antiproliferative effects in HR-deficient cancer cells.
- Combination with Olaparib significantly enhanced DNA damage and achieved 85% tumor growth inhibition in vivo.
- Compound 33 exhibited favorable pharmacokinetics and good tolerability.
Conclusions:
- Compound 33 is a potent Polθ inhibitor with significant synthetic lethality effects.
- It warrants further preclinical development as a targeted cancer therapeutic agent for HR-deficient cancers.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:31Homologous Recombination
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...